Amicus Therapeutics is a biotechnology company that was founded in 2002 in Cranbury, New Jersey. Its specialty is in advance therapy for a broad range of rare genetic diseases. Things like mutated proteins are studied at the company, and enzyme replacement therapy products are developed for many disorders like Fabry disease and Pompe disease, which are what is known as Lysososmal Storage Disorders, or LSDs.
The drug Galafold was developed by the company, and it is being used by over 100 patients for the treatment of these LSDs. Most of the users of the drug are in Germany, but it is also being introduced in places like France. Italy and the United Kingdom. Galafold helped Amicus Therapeutics generate enough sales to put the company on the New York Stock Exchange. Its NASDAQ trading name is FOLD. Know more about Amicus Therapeutics on dialdish.com.
In 2007, the company went public, and by 2008, it had expanded from just having one location in New Jersey to having another research site in San Diego, California. The Michael J. Fox Foundation gave Amicus Therapeutics a $500,000 grant in 2010 to support their studies on rare and orphan diseases. The company also received a grant from the Alzheimer’s Drug Discovery Foundation in the amount of $210,300 to further their research on Alzheimer’s Disease.
Led by CEO John Francis Crowley and President Bradley L. Campbell, Amicus Therapeutics acquired another company called Scioderm in 2015. Scioderm also specialized in treating rare diseases through biotechnology methods, which is defined as simply being technology that’s based on biology. Know more on gcreport.com about Amicus Therapeutics.
There are currently more than 200 biotechnology health care products and vaccines on the market, and many of them are being used to treat diseases that were once deemed untreatable. Amicus Therapeutics works to provide help for patients who have these types of rare diseases by continuing to create effective medicinal treatments.